Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 802 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HER2 Negative Breast Cancer Clear all

Conditions: Breast Cancer, Breast Neoplasms
Interventions: P10s-PADRE/ MONTANIDE™ ISA 51 VG, Doxorubicin, Cyclophosphamide, Docetaxel; Biological · Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Little Rock, Arkansas

Conditions: ER-Positive HER2-Negative Breast Cancer
Interventions: AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 64
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more

Conditions: Metastatic Breast Cancer
Interventions: Ribociclib, Palbociclib, Abemaciclib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 4,320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Breast Cancer
Interventions: RAD 001; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Early Breast Cancer
Interventions: Giredestrant, Anastrozole, Palbociclib, Surgery; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Burbank, California • Laguna Hills, California • San Luis Obispo, California + 7 more

Conditions: Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv, Metastatic Breast Cancer
Interventions: elacestrant, palbociclib, abemaciclib, ribociclib; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Chicago, Illinois

Conditions: Advanced/Metastatic Solid Tumors
Interventions: NMS-03305293; Drug
Lead sponsor: Nerviano Medical Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Triple Negative Breast Cancer
Interventions: Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 17 more

Conditions: Breast Neoplasms, Breast Cancer, Estrogen-receptor Positive Breast Cancer, Cancer, Breast, Breast Cancer Female, Breast Adenocarcinoma, Estrogen Receptor Positive Tumor, ER Positive
Interventions: H3B-6545; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 23
States / cities: Goodyear, Arizona • Los Angeles, California • San Francisco, California + 18 more

Conditions: ER+ HER2- Advanced Breast Cancer
Interventions: AZD9496; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: Sarasota, Florida • New York, New York • Nashville, Tennessee

Conditions: Estrogen Receptor Negative (ER-Negative) Breast Cancer, Progesterone Receptor Negative (PR-Negative) Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer, Brain Metastases
Interventions: INIPARIB + irinotecan; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 13
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 10 more

Conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, PIK3CA Mutation, HER2- Negative Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor, Cervical Cancer
Interventions: RGT-490; Drug
Lead sponsor: Regor Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Pittsburgh, Pennsylvania • Houston, Texas + 2 more

Conditions: Breast Cancer
Interventions: Inavolisib, Placebo, Palbociclib, Fulvestrant; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: Beverly Hills, California • Boston, Massachusetts • New York, New York + 7 more

Conditions: HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Interventions: PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 39
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more

Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
Interventions: Samuraciclib, Fulvestrant; Drug
Lead sponsor: Carrick Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Ocala, Florida • Baltimore, Maryland • Kansas City, Missouri + 2 more

Conditions: Breast Cancer
Interventions: Nivolumab, Ipilimumab, Nab-paclitaxel; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 5 more

Conditions: Breast Cancer
Interventions: MRI, Lumbar puncture; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Breast Cancer
Interventions: Bavituximab, Taxane; Biological · Drug
Lead sponsor: Peregrine Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Bakersfield, California • Tinley Park, Illinois

Conditions: Triple Negative Breast Cancer
Interventions: Pembrolizumab, Paclitaxel, Capecitabine; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 2
States / cities: Los Angeles, California • Portland, Oregon

Conditions: Breast Cancer
Interventions: Temsirolimus, Neratinib; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 4
States / cities: Goodyear, Arizona • Los Angeles, California • New York, New York

Conditions: Metastatic Breast Cancer
Interventions: WX-671, placebo; Drug
Lead sponsor: Heidelberg Pharma AG; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania

Conditions: Adult Solid Neoplasm, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 3
States / cities: Hershey, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: allogeneic GM-CSF-secreting breast cancer vaccine, recombinant interferon alfa, cyclophosphamide; Biological · Drug
Lead sponsor: Wiseman Research Initiatives LLC; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Glendale, California • Los Angeles, California

Conditions: Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer
Interventions: Alpelisib, Fulvestrant, Aromatase inhibitor; Drug
Lead sponsor: Marina N Sharifi; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 4
States / cities: Chicago, Illinois • Omaha, Nebraska • Hershey, Pennsylvania + 1 more

Search by objective public record fields.

Vaccination of High Risk Breast Cancer Patients - A Combined Phase I/II Feasibility-and-Efficacy Study

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

Trial of RAD001 in Triple Negative Metastatic Breast Cancer

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

AZD9496 First Time in Patients Ascending Dose Study

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

A Study of PF-06873600 in People With Cancer

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer